The Advanced Medical Technology Association (AdvaMed) has expressed support for the Trump administration’s AI action plan.
Revealed by the White House on 23 July, the AI action plan comes in accordance with a January executive order from President Trump to remove barriers to American leadership in AI.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Key policies of the plan that are most likely to affect healthcare include removing federal regulations that hinder AI development and deployment to enable innovation and adoption. Plans to update federal procurement guidelines to ensure the government only contracts with frontier large language model (LLM) developers who ensure that their systems are “objective and free from top-down ideological bias” may also influence the healthcare space moving forward.
AdvaMed president and CEO Scott Whitaker said: “We share the White House’s goal to lead the world in AI development to improve Americans’ quality of life and drive domestic economic growth.
“AI in healthcare is already transforming lives, with earlier, faster, and more accurate diagnoses, sparing patients unnecessary procedures and saving them and the healthcare system time and money. A recent study found that mammography AI led to a 29% increase in early breast cancer detection.
“That is truly remarkable. And there is much more to come from medtech.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe AI action plan also outlines plans to export American AI and expedite and modernise permits for datacentres and semiconductor labs in the US.
Michael Kratsios, policy director at the White House’s Office of Science and Technology, said: “This plan galvanises federal efforts to turbocharge our innovation capacity, build cutting-edge infrastructure, and lead globally, ensuring that American workers and families thrive in the AI era.”
The AI action plan will continue the Trump administration’s keen focus on the technology. AI is also having an impact on processes at the US Food and Drug Administration (FDA). Under the leadership of FDA commissioner Dr Martin Makary, the agency adopted Elsa, a generative AI tool intended to increase efficiency, last month.
The use of AI in healthcare is rapidly advancing, with GlobalData analysis showing the market is projected to reach a valuation of around $19bn by 2027.
Since Trump returned to the White House in January 2025, the list of FDA-authorised products using AI has swelled by over 100 to more than 1,200 in total, with the most common device applications in radiology.
